Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 18/20 | 0.50 |
| ▸ | HTR2A | P28223 | 4/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tert-Butyl Formate SCHEMBL27986724 | 0.90 | HTR6 (0.44) | HTR6HTR2AHTR2BHTR1ADRD2 | |
| SCHEMBL2450282 | 0.89 | HTR6 (0.61) | HTR6HTR2AHTR2BHTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL951642 | 0.88 | HTR6 (0.60) | HTR6HTR2AHTR2BHTR1ADRD2 | |
| SCHEMBL948371 | 0.84 | HTR6 (0.48) | HTR6HTR2AHTR2BHTR1ADRD2 | |
| SCHEMBL950399 | 0.83 | HTR6 (0.51) | HTR6HTR2AHTR2BHTR1ADRD2 | |
| SCHEMBL952720 | 0.83 | HTR6 (0.55) | HTR6HTR2AHTR2BHTR1ADRD2 | |
| SCHEMBL946338 | 0.83 | HTR6 (0.53) | HTR6HTR2AHTR2BHTR1ADRD2 | |
| SCHEMBL2450686 | 0.80 | HTR6 (0.40) | HTR6HTR2AHTR2BHTR1ADRD2 | |
| SCHEMBL27774717 | 0.79 | HTR6 (0.45) | HTR6HTR2AHTR2BHTR1ADRD2 | |
| SCHEMBL27986723 | 0.78 | HTR6 (0.51) | HTR6HTR2AHTR2BHTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101679351-B | Quinoline compounds suitable for treating didorders that respond to modulation of the serotonin 5-ht6 receptor | ABBVIE GMBH & CO KG | 2015-01-07 | — | — | CN | claimed |
| EP-2139880-B1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2011-09-14 | — | — | EP | claimed |
| CN-101679351-B | Quinoline compounds suitable for treating didorders that respond to modulation of the serotonin 5-ht6 receptor | ABBVIE GMBH & CO KG | 2015-01-07 | — | — | CN | disclosed |
| US-8242102-B2 | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2012-08-14 | — | — | US | disclosed |
| EP-2139880-B1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-20110009380-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2011-01-13 | — | — | US | disclosed |
| EP-2139880-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DIDORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008116831-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DIDORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009380-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | HTR2C, HTR3B, HTR1B | HTR6 6/4885HTR2A 5/4885HTR2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.